US · LFCR
Lifecore Biomedical, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Chaska, MN 55318
- Website
- lifecore.com
Price · as of 2025-05-25
$5.26
Market cap 269.76M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $87.47 | +1,562.93% |
| Intrinsic Value(DCF) | $2.80 | -46.77% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $5.92 | $24.83 | $31.08 | $4.51 | $3.51 |
| 2012 | $8.66 | $24.77 | $116.96 | $6.38 | $11.03 |
| 2013 | $14.04 | $35.61 | $534.51 | $9.37 | $39.73 |
| 2014 | $12.15 | $28.68 | $533.26 | $9.29 | $11.27 |
| 2015 | $13.09 | $27.06 | $183.13 | $8.76 | $10.32 |
| 2016 | $12.04 | $29.40 | $0.00 | $3.81 | $0.00 |
| 2017 | $13.10 | $28.09 | $0.00 | $8.17 | $2.54 |
| 2018 | $13.35 | $27.62 | $0.00 | $11.63 | $5.92 |
| 2019 | $11.23 | $22.59 | $0.00 | $7.19 | $1.07 |
| 2020 | $10.32 | $240.82 | $0.00 | $0.00 | $78.54 |
| 2021 | $10.76 | $96.25 | $0.00 | $0.25 | $30.05 |
| 2022 | $10.42 | $95.28 | $0.00 | $0.00 | $0.00 |
| 2023 | $10.46 | $24.63 | $0.00 | $0.00 | $0.00 |
| 2024 | $5.61 | $107.10 | $0.00 | $1.89 | $12.33 |
| 2025 | $6.99 | $87.47 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Lifecore Biomedical, Inc.'s (LFCR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $87.47
- Current price
- $5.26
- AI upside
- +1,562.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.80
-46.77% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LFCR | Lifecore Biomedical, Inc. | $5.26 | 269.76M | +1,563% | -47% | — | — | -6.29 | 182.17 | 1.89 | -41.53 | — | -14.53 | 31.27% | -13.38% | -30.04% | -612.08% | -13.25% | -15.70% | 97.92 | -0.79 | 2.84 | 1.72 | -13.91 | -48485.00% | 47.00% | -2490.00% | -5.60% | -0.01 | -10.46% | 0.00% | 0.00% | 1.05% | -21.22 | -26.87 | 2.84 | -0.01 |
| ACB | Aurora Cannabis Inc. | $3.84 | 217.76M | +498% | -40% | +80% | -82% | 27.82 | 0.78 | 1.28 | 6.97 | — | 0.92 | 54.65% | 1.44% | 0.46% | 2.80% | 0.80% | 1.87% | 0.18 | 0.59 | 4.31 | 2.06 | -1.56 | -10223.00% | 2701.00% | -9666.00% | -0.65% | 0.15 | -0.59% | 0.00% | 0.00% | 0.12% | 72.30 | -125.35 | 1.04 | -8.43 |
| ACHV | Achieve Life Sciences, In… | $4.56 | 242.75M | — | — | — | — | -2.53 | 4.82 | — | -2.04 | — | 5.33 | 0.00% | — | — | -409.51% | 2085.90% | -137.33% | 0.48 | -17.92 | 5.46 | 5.14 | 0.07 | -1733.00% | — | 2151.00% | -29.56% | -4.46 | 1589.43% | 0.00% | 0.00% | 3.93% | -1.95 | -2.56 | — | -6.45 |
| BIOA | BioAge Labs, Inc. | $22.27 | 798.49M | — | — | — | — | -0.69 | 0.15 | — | 4.33 | — | 0.15 | 0.00% | — | — | -94.98% | 95.18% | -37.02% | 0.03 | -33.04 | 12.86 | 12.76 | 5.04 | -2246.00% | — | 3826.00% | -106.31% | -1.85 | 63.16% | 0.00% | 0.00% | 772.94% | 3.80 | 5.72 | — | 0.23 |
| CGC | Canopy Growth Corporation | $1.12 | 576.26M | +725% | -39% | — | +204% | -0.42 | 0.52 | 0.95 | -0.99 | — | 0.72 | 29.56% | -43.55% | -222.35% | -122.35% | -14.04% | -54.48% | 0.72 | -1.57 | 3.12 | 1.95 | -0.49 | -3709.00% | -947.00% | -3809.00% | -69.30% | -1.76 | -21.21% | 0.00% | 0.00% | 102.99% | -4.03 | -2.67 | 1.76 | -16.18 |
| CVRX | CVRx, Inc. | $8.16 | 214.7M | +209% | -60% | — | — | -4.02 | 5.45 | 3.78 | -3.70 | — | 5.45 | 85.33% | -90.49% | -94.10% | -96.59% | -342.22% | -44.76% | 1.29 | -8.80 | 7.63 | 6.49 | 0.49 | -2302.00% | 1045.00% | 60.00% | -19.01% | -3.02 | -272.03% | 0.00% | 0.00% | 0.00% | -3.70 | -4.65 | 3.35 | -5.99 |
| IMMP | Immutep Limited | $2.80 | 412.14M | +523% | -76% | — | — | -5.97 | 2.55 | 72.72 | -3.80 | -35.82 | 2.69 | -1117.55% | -2506.49% | -1218.02% | -36.88% | -1019.26% | -34.27% | 0.01 | — | 11.69 | 10.17 | 1.05 | 1667.00% | 3128.00% | 7368.00% | -16.93% | -4.86 | -500.64% | 0.00% | 0.00% | 0.00% | -1.89 | -3.84 | 47.33 | 10.94 |
| OMI | Owens & Minor, Inc. | $2.68 | 207.07M | +942% | +49% | — | — | -2.12 | 1.36 | 0.07 | 48.40 | -0.28 | -0.72 | 20.74% | -1.94% | -3.39% | -48.70% | -7.35% | -7.44% | 3.79 | -1.44 | 1.08 | 0.39 | 35.40 | 76000.00% | 355.00% | -11251.00% | -8.69% | 0.09 | -2.36% | 0.00% | 0.00% | 0.00% | -13.75 | -42.87 | 0.27 | 2.30 |
| PRQR | ProQR Therapeutics N.V. | $1.59 | 167.5M | +4,852% | +2,420% | — | — | -4.80 | 1.50 | 7.05 | -0.05 | — | 1.50 | 100.00% | -161.18% | -146.86% | -41.35% | 56.30% | -17.34% | 0.19 | -28.29 | 3.95 | 3.84 | 5.48 | -286.00% | 19022.00% | -28740.00% | -28.37% | -0.94 | 70.36% | 0.00% | 0.00% | 16.97% | -0.04 | -0.03 | 0.06 | -2.22 |
| SGHT | Sight Sciences, Inc. | $5.16 | 272.82M | +483% | -76% | — | — | -2.30 | 1.35 | 1.48 | -0.83 | — | 1.35 | 85.50% | -63.27% | -64.49% | -49.59% | -403.80% | -33.29% | 0.46 | -10.84 | 9.04 | 8.48 | 1.74 | -965.00% | -147.00% | -5261.00% | -19.22% | -1.44 | -181.68% | 0.00% | 0.00% | 0.00% | -0.76 | -1.69 | 0.48 | -1.67 |
| TKNO | Alpha Teknova, Inc. | $2.58 | 138.11M | +974% | -63% | — | — | -7.38 | 1.85 | 3.14 | -13.45 | — | 2.24 | 33.17% | -41.90% | -42.59% | -22.83% | -21.20% | -15.52% | 0.22 | -23.91 | 4.58 | 1.40 | -0.91 | -4386.00% | 735.00% | -3170.00% | -7.25% | -1.07 | -11.53% | 0.00% | 0.00% | 13.58% | -8.04 | -14.79 | 3.37 | 0.52 |
About Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
- CEO
- Paul Josephs
- Employees
- 524
- Beta
- 0.59
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.80 ÷ $5.26) − 1 = -46.77% (DCF, example).